A phase III, 12-week, multicentre, double-blind, randomised, placebo- and active comparator-controlled, parallel group study to investigate the efficacy and safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in adults with rheumatoid arthritis.

Trial Profile

A phase III, 12-week, multicentre, double-blind, randomised, placebo- and active comparator-controlled, parallel group study to investigate the efficacy and safety of GW406381, 5mg, 10mg, 25mg, and 50mg administered orally once daily, in adults with rheumatoid arthritis.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs GW 406381 (Primary)
  • Indications Musculoskeletal pain; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Oct 2012 Planned number of patients changed from 2208 to 2210.
    • 20 May 2009 Additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top